UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report: May 31, 2018 (May 31, 2018)

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
 
98-0351734
(Commission File Number)
 
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
 
31905
(Address of Principal Executive Offices)
 
(Zip Code)

011 972 74 710 8607
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

On May 31, 2018, Pluristem Therapeutics Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”). The results of the stockholder voting at the 2018 Annual Meeting are set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
  
For
  
Against
  
Abstain
  
Broker Non-Votes
Zami Aberman
  
26,503,297
  
1,584,159
  
1,584,159
  
25,552,412
                 
Israel Ben-Yoram
  
25,006,894
  
2,250,264
  
950,163
  
25,552,412
                 
Isaac Braun
  
25,003,727
  
2,253,431
  
950,163
  
25,552,412
                 
Mark Germain
  
25,012,672
  
2,090,336
  
1,104,313
  
25,552,412
                 
Moria Kwiat
  
24,539,099
  
2,717,005
  
951,217
  
25,552,412
                 
Hava Meretzki
  
24,345,029
  
2,776,933
  
1,085,359
  
25,552,412
                 
Nachum Rosman
  
25,018,939
  
2,102,977
  
1,085,405
  
25,552,412
                 
Doron Shorrer
  
24,995,028
  
2,141,080
  
1,071,213
  
25,552,412
                 
Yaky Yanay
  
25,766,258
  
1,591,375
  
849,688
  
25,552,412
 
Proposal No. 2 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2018.

For
  
Against
  
Abstain
  
Broker Non-Votes
52,041,038
  
1,158,889
  
559,806
  
N/A
 
The results reported above are final voting results.

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
  
 
 
  
Date: May 31, 2018
By:
/s/ Erez Egozi
  
 
Name:
 Erez Egozi
  
 
Title:
Chief Financial Officer